XML 48 R33.htm IDEA: XBRL DOCUMENT
v3.21.2

Business Segment Information Business Segment Information (Tables) | 6 Months Ended
--- | ---
Sep. 30, 2021
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Financial information for each of our segments is presented in the following table:
|  | Three Months Ended September 30, |  | Six Months Ended September 30,
|  | 2021 |  | 2020 |  | 2021 |  | 2020
Revenues: |  |  |  | (*as adjusted) |  |  |  | (*as adjusted)
Healthcare |  | $ | 744,134 |  |  | $ | 470,927 |  |  | $ | 1,346,951 |  |  | $ | 870,585 |
Applied Sterilization Technologies |  | 204,892 |  |  | 169,547 |  |  | 413,794 |  |  | 321,909 |
Life Sciences |  | 132,327 |  |  | 115,658 |  |  | 253,798 |  |  | 232,570 |
Dental |  | $ | 115,632 |  |  | — |  |  | $ | 150,864 |  |  | $ | — |
Total revenues |  | $ | 1,196,985 |  |  | $ | 756,132 |  |  | $ | 2,165,407 |  |  | $ | 1,425,064 |
Operating income (loss): |  |  |  |  |  |  |  |
Healthcare |  | $ | 160,390 |  |  | $ | 104,796 |  |  | $ | 296,550 |  |  | $ | 188,968 |
Applied Sterilization Technologies |  | 99,789 |  |  | 76,835 |  |  | 201,716 |  |  | 140,790 |
Life Sciences |  | 57,519 |  |  | 46,433 |  |  | 106,607 |  |  | 94,894 |
Dental |  | 32,392 |  |  | — |  |  | 42,511 |  |  | — |
Corporate |  | (71,552) |  |  | (58,155) |  |  | (146,612) |  |  | (110,522) |
Total operating income before adjustments |  | $ | 278,538 |  |  | $ | 169,909 |  |  | $ | 500,772 |  |  | $ | 314,130 |
Less: Adjustments |  |  |  |  |  |  |  |
Amortization of acquired intangible assets (1) |  | $ | 74,791 |  |  | $ | 21,955 |  |  | $ | 116,531 |  |  | $ | 39,455 |
Acquisition and integration related charges (2) |  | 17,404 |  |  | 1,135 |  |  | 158,400 |  |  | 2,421 |
Redomiciliation and tax restructuring costs (3) |  | 159 |  |  | 384 |  |  | 110 |  |  | 554 |
Net (gain) loss on divestiture of businesses (1) |  | (15) |  |  | (5) |  |  | 404 |  |  | 5 |
Amortization of inventory and property "step up" to fair value (1) |  | 69,486 |  |  | 714 |  |  | 94,276 |  |  | 1,317 |
COVID-19 incremental costs (4) |  | — |  |  | 4,539 |  |  | — |  |  | 13,209 |
Restructuring charges (5) |  | 210 |  |  | (76) |  |  | 224 |  |  | 90 |
Total operating income |  | $ | 116,503 |  |  | $ | 141,263 |  |  | $ | 130,827 |  |  | $ | 257,079 |
Revenue from External Customers by Products and Services [Table Text Block] |
|  | Three Months Ended September 30, |  | Six Months Ended September 30,
|  | 2021 |  | 2020 |  | 2021 |  | 2020
Healthcare: |  |  |  |  |  |  |  |
Capital equipment |  | $ | 202,405 |  |  | $ | 131,673 |  |  | $ | 353,295 |  |  | 259,755
Consumables |  | 270,089 |  |  | 122,797 |  |  | 476,781 |  |  | 206,551
Service |  | 271,640 |  |  | 216,457 |  |  | 516,875 |  |  | 404,279 |
Total Healthcare Revenues |  | $ | 744,134 |  |  | $ | 470,927 |  |  | $ | 1,346,951 |  |  | $ | 870,585 |
Applied Sterilization Technologies Service Revenues |  | $ | 204,892 |  |  | $ | 169,547 |  |  | $ | 413,794 |  |  | $ | 321,909 |
Life Sciences: |  |  |  |  |  |  |  |
Capital equipment |  | $ | 34,186 |  |  | $ | 29,241 |  |  | $ | 66,931 |  |  | $ | 59,671 |
Consumables |  | 61,748 |  |  | 55,793 |  |  | 118,284 |  |  | 114,635 |
Service |  | 36,393 |  |  | 30,624 |  |  | 68,583 |  |  | 58,264 |
Total Life Sciences Revenues |  | $ | 132,327 |  |  | $ | 115,658 |  |  | $ | 253,798 |  |  | $ | 232,570 |
Dental Revenues |  | $ | 115,632 |  |  | $ | — |  |  | $ | 150,864 |  |  | $ | — |
Total Revenues |  | $ | 1,196,985 |  |  | $ | 756,132 |  |  | $ | 2,165,407 |  |  | $ | 1,425,064 |
Revenue from External Customers by Geographic Areas [Table Text Block] |
| Three Months Ended September 30, |  | Six Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Revenues: |  |  |  |  |  |  |
Ireland | $ | 20,046 |  |  | $ | 17,090 |  |  | $ | 41,991 |  |  | $ | 31,463 |
United States | 852,497 |  |  | 549,449 |  |  | 1,531,747 |  |  | 1,041,157 |
Other locations | 324,442 |  |  | 189,593 |  |  | 591,669 |  |  | 352,444 |
Total Revenues | $ | 1,196,985 |  |  | $ | 756,132 |  |  | $ | 2,165,407 |  |  | $ | 1,425,064 |
|  | September 30, 2021 |  | March 31, 2021
Property, Plant, and Equipment, Net |  |  |  |
Ireland |  | $ | 53,784 |  |  | 52,140 |
United States |  | 881,069 |  |  | 673,784 |
Other locations |  | 576,402 |  |  | 509,476 |
Property, Plant, and Equipment, Net |  | $ | 1,511,255 |  |  | $ | 1,235,400 |
Reconciliation of Assets from Segment to Consolidated | Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments. Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
|  | September 30, 2021 |  | March 31, 2021
Assets: |  |  |  |
Healthcare and Life Sciences |  | $ | 5,398,177 |  |  | $ | 3,600,182 |
Applied Sterilization Technologies |  | 3,029,090 |  |  | 2,974,289 |
Dental |  | 1,175,354 |  |  | — |
Cantel related goodwill not yet allocated (1) |  | 2,149,827 |  |  | — |
Total assets |  | $ | 11,752,448 |  |  | $ | 6,574,471 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration